Scientific Programme – Details

Tuesday, 16 November 2010

Opening Ceremony — **Room A-C**

13:00–13:15	Opening remarks	
	J.Y. Blay (France)	EORTC
	J. Doroshow (USA)	NCI
	M. Foti (USA)	AACR

Room A-C

		Abstract number
13:15–14:00	**Michel Clavel lecture** Chair: A. Awada (Belgium)	
13:15	Novel molecular imaging for early drug development *E.G.E. de Vries (The Netherlands)*	1

Room A-C

		Abstract number
14:00–14:45	**Keynote lecture** Chair: L.C. Cantley (USA)	
14:00	Resistance to targeted therapy: mechanisms and therapeutic implications *P. Jänne (USA)*	2

Plenary session 1 — **Room A-C**

		Abstract number
15:15–17:00	**Tumour stem cells: At the crossroads?** Chairs: P. LoRusso (USA) and R. de Maria (Italy)	
15:15	Are cancer stem cells relevant? *J. Dick (Canada)*	3
15:40	Cancer stem cells and radiotherapy *M. Krause (Germany)*	4
16:05	Drug sensitivity of cancer stem cells *R. De Maria (Italy)*	5
16:30	Challenges in clinical development of stem-cell therapy *P. LoRusso (USA)*	6

Wednesday, 17 November 2010

Workshop 1 **Room A**

		Abstract number
08:00–09:45	**Characterising the target for improved drug tailoring** Chairs: J. Verweij (The Netherlands) and J. De Bono (United Kingdom)	
08:00	Assessing target functionality for drug and patient tailoring: a clinical perspective *J. Verweij (The Netherlands)*	7
08:25	Pharmacodynamic markers of targeted agents *A. Adjei (USA)*	8
08:50	Pharmacoepigenetics and epigenetic drugs *M. Esteller (Spain)*	9
09:15	Biosample collection in clinical trials *J. Hall (Belgium)*	10

Workshop 2 **Room B**

		Abstract number
08:00–09:45	**Pharmacogenetics and pharmacogenomics in cancer** Chairs: R. Danesi (Italy) and S. Loi (Belgium)	
08:00	To genotype or to phenotype: that's the question *R.H.J. Mathijssen (The Netherlands)*	11
08:20	Pharmacogenetics of drug transporters *R. Danesi (Italy)*	12
08:40	The role of gene expression profiling in early drug development *S. Loi (Belgium)*	13
09:00	Genomic versus histological grading in soft tissue sarcomas *J. Coindre (France)*	14
09:20	Microarray and validation analyses performed on melanoma metastases identify TYRP1 as a prognostic marker for both DMFS and OS *G. Ghanem (Belgium)*	15

Workshop 3 **Room C**

		Abstract number
08:00–09:45	**European and US initiatives for early drug development** Chairs: J.M. Collins (USA) and J. Blay (France)	
08:00	Molecular driven clinical trials: The EORTC Network Of Core Institutions (NOCI) Perspectives *D. Lacombe (Belgium)*	16
08:25	NCI initiatives in developmental therapeutics *J.M. Collins (USA)*	17
08:50	The Neo BIG programme *M. Piccart (Belgium)*	18
09:15	The UK Network of Experimental Cancer Medicine Centres *P.W.M. Johnson (United Kingdom)*	19

Workshop 4 **Room A**

		Abstract number
10:15–12:00	**Rational use of targeted therapies** Chairs: J. Doroshow (USA) and J. Baselga (USA)	
10:15	Re-inventing the methodology of early drug development *J. Doroshow (USA)*	20
10:40	Rational combination therapies *J. Baselga (USA)*	21
11:05	Success and pitfalls of targeted therapy combinations *R. Schilsky (USA)*	22
11:30	Targeted agents combined with radiation *E. Deutsch (France)*	23

Workshop 5 **Room B**

		Abstract number
10:15–12:10	**Pharmacokinetics/pharmacodynamics in cancer** Chairs: J. Tabernero (Spain) and M. Hidalgo (Spain)	
10:15	Factors affecting the pharmacokinetics (PK) and pharmacodynamics (PD) of nanoparticle and nanosomal anticancer agents *W. Zamboni (USA)*	24
10:40	Role of pharmacokinetics/Pharmcodynamics in dose selection of molecular targeted therapies *J.H.M. Schellens (The Netherlands)*	25
11:05	Is a side effect of molecular targeted therapy a marker of efficacy? *J. Tabernero (Spain)*	26
11:30	Drug response in a genetically engineered mouse: clinical implications *M. Hidalgo (Spain)*	27
11:55	Targeting the PI3K/mTOR pathway in genetically engineered mouse models of advanced prostate cancer *A. Patnaik (USA)*	27A

Workshop 6 **Room C**

		Abstract number
10:15–12:00	**New drug development in the 21st century: Do we need to break from tradition?** Chairs: M. Piccart (Belgium) and E. Eisenhauer (Canada)	
10:15	The point of view of academia *M. Piccart (Belgium)*	28
10:30	In search of intermediate endpoints *E. Eisenhauer (Canada)*	29
10:45	Innovation, collaboration, and agility: essential characteristics for the biopharmaceutical industry in the 21st century *M.L. Rothenberg (USA)*	30
11:00	The point of view of EMEA *F. Pignatti (USA)*	31
11:15	The point of view of FDA *R. Justice (USA)*	32
11:30	Discussion	

Special Lecture **Room A-C**
Chair: L.C. Cantley (USA) Abstract number

14:05–14:45	Hallmarks of cancer, ten years later: evolving principles, and therapeutic targeting *D. Hanahan (Switzerland)*	33

Plenary session 2 **Room A-C**
Abstract number

14:45–16:15	**Proffered paper session** Chairs: J. Doroshow (USA) and A. Awada (Belgium)	
14:45	Development and validation of robust immunohistochemical assays for phospho-histone-H3 and Eg5 as pharmacodynamic biomarkers to support Eg5 inhibitor (LY2523355) clinical trials in patients with advanced malignancies *A. Nasir (USA)*	1LB[1]
15:00	DNA amplifications of kinase inhibitor targets in human cancer *M.J. Anstett (USA)*	34
15:15	Mutational analysis of epithelial ovarian cancer using OncoMap *U. Matulonis (USA)*	35
15:30	Development and validation of a novel multiplexed PCR-coupled liquid bead array system for gene expression in circulating tumor cells *A. Markou (Greece)*	36
15:45	An epithelial to mesenchymal transition (EMT) gene expression signature identifies Axl as an EMT marker in non-small cell lung cancer (NSCLC) and head and neck cancer (HNC) lines and predicts response to erlotinib *L. Byers (USA)*	37

Plenary session 3 **Room A-C**
Abstract number

16:30–18:30	**New targets and inhibitors** Chairs: L.C. Cantley (USA) and P. Schöffski (Belgium)	
16:30	The lysosomal cell death pathway *M. Jäättelä (Denmark)*	38
16:50	Update on polo-like kinase inhibitors in early clinical testing *P. Schöffski (Belgium)*	39
17:10	Metformin: What are the targets of this potential anti-cancer agent? *P.J. Goodwin (Canada)*	40
17:30	Applications of the inhibition of Mdm2 function in Cancer Therapy *D. Lane (Singapore)*	41
17:50	New inhibitors targeting critical cancer dependencies: Progress and challenges *P. Workman (United Kingdom)*	42
18:10	Targeting PI3K: where are we? *L. Cantley (USA)*	43

[1] Late breaking oral abstract, see p. 3.

Poster Sessions

Late breaking posters

Abstract number

A first synthesis of [18F]-lapatinib: a new agent for positron emission tomographic studies of kinase receptors 4LB[2]
G.L. Griffiths, F. Basuli, H. Wu, C. Li, J.L. Tatum, J.H. Doroshow

Anti-tumor activity of MPC-9528, GMX1778 and APO866: Nampt inhibitors of three different structural classes 5LB[3]
J.J. Boniface, V.R. Baichwal, L. DeMie, J.P. Green, W.R. Judd, J.W. Lockman, D.I. Papac, R.T. Terry-Lorenzo, J.A. Willardsen, R.O. Carlson

The Nampt inhibitor MPC-9528 and the PARP inhibitor olaparib synergize in killing a BRCA-deficient cancer cell line 6LB[4]
R.T. Terry-Lorenzo, T.C. Fleischer, J.W. Lockman, J.J. Boniface, J.A. Willardsen, R.O. Carlson

Cancer vaccines

Poster board — Abstract number

001 Vaccination of dendritic cells pulsed with tumor endothelial cells inhibits tumor growth 44
N. Utoguchi, R. Suzuki, Y. Oda, T. Nomura, K. Maruyama

002 Preliminary results of a phase 1 study of intravenous administration of GL-ONC1 vaccinia virus including green-fluorescent protein real time imaging in patients with advanced cancer 45
J. Vitfell-Pedersen, E.M. Karapanagiotou, S. Alam, M. Puglisi, L. Britton, S. Sassi, D. Mansfield, T. Yap, J. De-Bono, K. Harrington

003 Immunotherapy with the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumors – clinical efficacy and immunological results of a phase I study 46
M.R. Weihrauch, M.S. von Bergwelt-Baildon, U. Hacker, H. Richly, U. Holtick, M. Tschaika, M. Schmidt, B. Wittig, B. Nokay, M.E. Scheulen

004 Immunotherapy with the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumors – safety results of a clinical phase I study 47
M.R. Weihrauch, H. Richly, M.S. von Bergwelt-Baildon, U. Hacker, A. Shimabukuro-Vornhagen, B. Nokay, M. Tschaika, M. Schmidt, B. Wittig, M.E. Scheulen

005 A novel method to improve antigen presentation and immunopotency of RNA-loaded monocyte-derived dendritic cells 48
I. Tcherepanova, A. Raney, B. Martin, M. Norris, T. Monesmith, M. DeBenedette, D. Healey, F. Miesowicz, C. Nicolette

006 A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins 49
E. Quaglino, C. Mastini, F. Riccardo, E. Ercole, M. Montani, G. Forni, F. Cavallo

Molecular-targeted therapies – preclinical

Poster board — Abstract number

007 A phase I study of the safety, tolerability and pharmacokinetics of pazopanib (P) in combination with gemcitabine (G) for advanced solid tumors 50
H. Richly, S.D. Rubin, A. Madi, M. Jeffels, B. Nokay, D. Gibson, S. Weller, M.E. Scheulen, R. Plummer

008 Deacetylation and inactivation of peroxiredoxin by SIRT2 increases sensitivity of breast cancer cells to oxidative stress 51
V. Coothan Kandaswamy, J. Chen, W. Fiskus, R. Rao, S. Nalluri, K. Buckley, R. Balusu, K. Bhalla

009 Discovery of novel fused thiadiazoles as potent inhibitors of phosphoinositide-3-kinase (PI3K) and/or the mammalian target of rapamycin (mTOR) 52
J. Pastor, G. Kurz, M.R. Rico Ferreira, D. Soilan, M.A. Ortega, S. Martinez, O. Rabal, I. Palacios, A. Cebria, J.R. Bischoff

---

[2] Late breaking poster abstract, see p. 4.
[3] Late breaking poster abstract, see p. 4.
[4] Late breaking poster abstract, see p. 4.

Monoclonal antibodies and targeted toxins/nuclides/agents

Thursday, 18 November 2010

Plenary session 4 **Room A-C**

Abstract number

08:00–09:45 **Targeting checkpoints/DNA repair in cancer**
Chairs: H. Calvert (United Kingdom) and H. Piwnica-Worms (USA)

08:00 The concept of synthetic lethality 242
H. Calvert (United Kingdom)

08:25 Targeting the Chk1/Cdc25A pathway in p53-deficient tumors 243
H. Piwnica-Worms (USA)

08:50 PARP inhibitors 244
J. De Bono (United Kingdom)

09:15 Targeting ATM and p53 245
M. Kastan (USA)

Plenary session 5 **Room A-C**

Abstract number

10:15–12:00 **New modalities of anticancer treatment**
Chairs: N. Zaffaroni (Italy) and W.D. Figg (USA)

10:15 New platforms of immunoconjugates 246
M. Sliwkowski (USA)

10:35 Dual function BAFF receptor aptamers inhibit ligand induced proliferation and deliver siRNAs to NHL cells 247
K. Tiemann (USA)

10:55 Targeting TRAIL receptors with genetically-engineered CD34+ stem cells 248
C. Carlo-Stella (Italy)

11:15 The state of nanotechnology for targeted treatment delivery 249
A. Urtti (Finland)

11:35 Targeted imaging and radionuclide therapy of somatostatin receptor positive tumours 250
F. Forrer (Switzerland)

Special Lecture **Room A-C**

Chair: J. Doroshow (USA) Abstract number

14:05–14:45 Lessons learnt of 20 years of targeted therapies 251
A. Awada (Belgium)

Plenary session 6 **Room A-C**

Abstract number

14:45–16:15 **Proffered papers**
Chairs: L.C. Cantley (USA) and D.A. Cameron (United Kingdom)

14:45 Anti-tumor activity of anti-RON antibodies and biomarker of response 2LB[5]
M. Han (USA)

15:00 Polyclonal resistance to kinase inhibition in GIST: Mechanisms and therapeutic strategies 252
J. Fletcher (USA)

[5] Late breaking oral abstract, see p. 3.

15:15	Screening for PIK3CA, RAS, and RAF mutations in trials with PI3K/AKT/mTOR signaling pathway inhibitors *F. Janku (USA)*	253
15:30	cKIT overexpression and wild-type NRAS/BRAF predict response to the tyrosine kinase inhibitor dasatinib in melanoma cell lines *F. Journe (Belgium)*	254
15:45	Transcriptome sequencing of upper aerodigestive tract cancer cell lines to reveal potential therapeutic targets *J. Braegelmann (USA)*	255
15:00	MEDI-573, a dual IGF-1/-2 neutralizing antibody, blocks IGF-1R and IR-A signaling and maintains glucose homeostasis in a Phase 1 study for advanced solid tumors *M. Menefee (USA)*	3LB[6]

Plenary session 7 **Room A-C**

Abstract number

16:30–18:30	**Selected tumours as a niche for targeted therapies** Chairs: A. Awada (Belgium) and J.-C. Soria (France)	
16:30	Emerging therapies in melanoma *A. Eggermont (The Netherlands)*	256
17:00	Recent advances in the treatment of refractory thyroid cancer: the use of kinase inhibitors *M. Schlumberger (France)*	257
17:30	Biology and treatment of thymoma *G. Giaccone (USA)*	258
18:00	Non small cell lung cancer molecular subtypes: therapeutic implications *J.-C. Soria (France)*	259

Poster Sessions

Animal models

Poster board Abstract number

001	Multi-modality in vivo imaging of bone metabolism and tumor growth in a mouse model of bone metastasis *D. Lister, M. Woolliscroft, V. Kaimal, P. McConville*	260
002	Effects of isoflurane anesthesia on bioluminescence measurements: impact on pharmacological assessment of anti-tumor activity of chemical entities *C. Schnell, S. Arnal, S. Barbé, M. Becquet, C. Garcia-Echeverria, R. Cozens*	261
003	Establishment of patient-tumor derived xenograft models for testing anticancer agents *C. Liu, W.W. Li, B. Li, R. Liu, W. Zhou, W.P. Huang, F. He, C. Bai*	262
004	A non-invasive bioluminescent imaging technique for monitoring shutdown of the tumour vasculature *A.C. O'Farrell, P.A. Cooper, R.A. Falconer, M.C. Bibby, J.H. Gill, S.D. Shnyder*	263
005	Establishment of a targeted fluorescence guided colonoscopy for a xenograph orthotopic colorectal cancer model *C. Dierkes, A. Rexin, B. Wiedenmann, P. Schulz, C. Grötzinger*	264
006	Rac1 is a therapeutic target for pancreatic cancer prevention and treatment *C. Lubeseder-Martellato, I. Heid, B. Sipos, S. Rieder, R.M. Schmid, J.T. Siveke*	265
007	Monitoring of pancreatic ductal adenocarcinoma in mouse models via multiparametric magnetic resonance imaging *I. Heid, M. Trajkovic-Arsic, M. Gretzinger, Y. Kosanke, A. Steingoetter, E.J. Rummeny, R.M. Schmid, J.T. Siveke, R. Braren*	266

[6] Late breaking oral abstract, see p. 3.

Clinical methodology

Poster board Abstract number

Combinatorial chemistry, drug screening and synthesis

Poster board Abstract number

Drug resistance and modifiers

Poster board Abstract number

Drug targets

Poster board Abstract number

Molecular-targeted therapies – clinical trials

Poster board Abstract number

Nanotechnology, drug delivery, new formulations, prodrugs

Natural products, new cytotoxics, clinical trials

Structure–activity relationship

Toxicology-side effects

Friday, 19 November 2010

Poster Discussion session **Room A-C**

Abstract number

09:30–10:30 **Angiogenesis and tumour microenvironment**

Chair: F. Eskens (The Netherlands)

09:30 Pharmacodynamic evaluation of pCDC2 and Wee1 signature as biomarkers of target engagement for the Wee1 tyrosine kinase inhibitor MK-1775 651
J.D. Cheng (USA)

09:35 Atrimers as a novel class of potent trimeric therapeutics inducing cancer cell death 331
A. Kretz Rommel (USA)

09:40 Use of functional human cancer cell line mitochondria to explore the mechanisms of ABT-737-induced mitochondrial membrane permeabilization 581
A. Borgne-Sanchez (France)

Discussant: F. Eskens (The Netherlands)

Chair: C. Dittrich (Austria)

10:00 A Phase 1 dose escalating study of ACE-041, a novel inhibitor of ALK-1 mediated angiogenesis, in patients with advanced solid tumors 465
S. Sharma (USA)

10:05 PI3K inhibition is necessary and sufficient to induce an anti-angiogenic response in vivo based on suppression of tumor vascular structure 466
D. Sampath (USA)

10:10 89Zr-bevacizumab PET imaging in renal cell carcinoma patients: feasibility of tumor VEGF quantification 221
S.F. Oosting (The Netherlands)

Discussant: C. Dittrich (Austria)

Plenary session 8 **Room A-C**

Abstract number

11:00–13:05 **Angiogenesis and tumour microenvironment**
Chairs: C.J.A. Punt (The Netherlands) and L.M. Ellis (USA)

12:15 Immunotherapy in 2010 – still alive? 463
C. Punt (The Netherlands)

11:50 Micro-environmental influences on cancer stem cells 462
L. Ellis (USA)

11:00 Antiangiogenic drug alterations of the tumor microenvironment which can impact chemotherapy efficacy 460
R. Kerbel (Canada)

11:25 Third generation anti-angiogenic strategies: novel players, novel principles 461
P. Carmeliet (Belgium)

12:40 Molecular imaging of therapy response 464
W. Weber (Germany)

Poster Sessions

Angiogenesis, metastasis and inhibitors

Cell-cycle-interactive agents

Poster board Abstract number

Radiation interactive agents

Poster board — Abstract number

DNA repair and inhibitors

Poster board — Abstract number

Gene therapy and antisense approaches

Poster board Abstract number

Genetics and epigenetics

Poster board Abstract number

Pharmacogenetics

Poster board Abstract number

RNA and DNA based technologies

Poster board Abstract number

Bioinformatics

Poster board Abstract number

Anthracyclines, antimetabolites, antimicrotubules, topoisomerase inhibitor

Poster board Abstract number

Apoptosis, necrosis, autophagy

Poster board Abstract number

Biomarkers

Poster board Abstract number

Chemoprevention

Poster board Abstract number

Hormonal agents

Poster board Abstract number

Immune system